Global Medical REIT (XRN) Financials

Global Medical REIT’s Q2 2026 results show stronger cash generation but continued reliance on financing and nonrecurring items. Operating cash flow increased to $22.6 million from $13.4 million in Q1 2026 and $22.1 million in Q2 2025. The improvement was supported by positive changes in operating assets and liabilities, along with steady depreciation and amortization add-backs.

Reported consolidated net income surged to $72.3 million, compared with $1.7 million in Q1 2026 and a $5.9 million loss in Q4 2025. However, nearly all of Q2’s profit came from $71.9 million of discontinued operations. Continuing operations produced only $410,000, indicating that the headline earnings improvement may not represent the ongoing performance of the business.

The balance sheet expanded during the quarter. Total assets rose to $1.37 billion from $1.24 billion at Q1 2026, largely because net premises and equipment increased to $1.04 billion. Total liabilities declined to $687.7 million from $717.4 million, while total equity and noncontrolling interests increased to $684.1 million. Cash and equivalents also improved to $10.7 million, although the company remained relatively liquid-light compared with its debt obligations.

• Operating cash flow remains positive and improved: Q2 operating cash flow of $22.6 million was the strongest reported quarter in the available 2025-2026 period and exceeded the $13.8 million of dividend payments shown in the cash flow statement.
• Debt declined sequentially: Short-term debt fell to $632.0 million from $662.3 million at the end of Q1 2026, contributing to a reduction in total liabilities.
• Asset growth accelerated: Net premises and equipment increased by approximately $122.3 million from Q1 2026, suggesting expansion of the company’s property base.
• Cash balances improved: Cash and equivalents rose from $8.2 million to $10.7 million during Q2, while the company also held $2.3 million in interest-bearing deposits and $10.9 million in trading securities.
• No impairment charge was recorded: The income statement reported zero impairment expense in Q1 and Q2 2026, which is favorable for property values and reported earnings.
• Investing activity was highly active: The company purchased $279.9 million of investment securities and sold or matured $211.4 million, producing a net investing cash outflow of $71.9 million. This may reflect portfolio repositioning rather than core operating growth.
• Financing activity provided liquidity: The company issued $224.0 million of debt while repaying $255.0 million, resulting in a net financing inflow of $51.3 million after dividends. This helped offset investing outflows but does not represent internally generated growth capital.
• Continuing profitability remains weak: Continuing-operations income was only $410,000 in Q2 2026, down from $1.7 million in Q1 and below the $2.4 million reported in Q1 2025.
• Interest costs continue to rise: Long-term debt interest expense increased to $8.8 million in Q2 2026 from $7.2 million in Q1 and $8.0 million in Q2 2025. Cash interest paid also rose to $7.0 million from $6.5 million in Q1.
• Leverage remains elevated: Short-term debt of $632.0 million represented roughly 46% of total assets at quarter-end, while retained earnings remained deeply negative at approximately $303.7 million.

Overall, the financial statements present a mixed picture for investors. Recurring cash flow and sequential debt reduction are constructive, and Q2 operating cash flow was sufficient to cover the reported dividend payment. Nevertheless, continuing earnings are thin, interest expense is rising, and the large Q2 profit was overwhelmingly driven by discontinued operations. Investors should focus on whether future quarters can sustain operating cash flow, reduce debt without relying on new borrowing, and improve earnings from continuing operations.